IMUBIND® PAI-2 ELISA
INTENDED USE
The IMUBIND® PAI-2 ELISA is an enzyme-linked immunoassay for the determination of human PAI-2 in human biological fluids.
This assay is for research use only. It is not intended for diagnostic or therapeutic procedures.
EXPLANATION OF THE TEST
This assay detects the low molecular weight (48 kD) and the high molecular weight glycosylated (60 kD) form of PAI-2. Free PAI-2 and PAI-2/uPA and PAI-2/tPA complexes are recognized. The assay is insensitive to PAI-1.
PRINCIPLE OF THE METHOD
Diluted samples are added to microwells coated with a polyclonal antibody against human PAI-2. During an incubation period, PAI-2 present in the sample will bind to the antibody coated to the wells. Following a washing step, a biotinylated monoclonal anti-PAI-2 antibody is added to the microwells and binds to the PAI-2 protein captured on the plate during a short incubation period. A streptavidin-horseradish peroxidase conjugate (SA-HRP) is added to the microwells to complete the formation of the antibody-enzyme detection complex. Following another washing step, the addition of a perborate-3,3’-5,5’-tetramethylbenzidine (TMB) substrate and its subsequent reaction with the HRP present generates a blue colored solution. The reaction is stopped by adding citrate stop solution, which turns the solution color yellow. Measuring the solution absorbance at 450 nm and extrapolating the value with those of a standard curve determines the level of PAI-2 in the samples.
Category: Research use only
Type: ELISA
Product Availability: Worldwide
Manufacturer: ImmBioMed GmbH & Co KG, Germany
For more information please click .pdf icon below.
IMUBIND PAI-2 ELISA
Cat.No. ADG823
Artikelnr.: 938129
Einheit: 96 Tests
Code: ADG823
Hersteller: ImmBioMed GmbH & Co. KG
BIBLIOGRAPHY
- The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Foekens JA et al., Cancer Res. 2000 Feb 1;60(3):636-643.
- Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer. Foekens JA et al., Cancer Res. 1995 Apr 1;55(7):1423-1427.
- Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer. Casslén B et al., Eur J Cancer. 1994;30A(9):1302-1309.
- Longitudinal assessment of maternal endothelial function and markers of inflammation and placental function throughout pregnancy in lean and obese mothers. Stewart FM et al., J Clin Endocrinol Metab. 2007 Mar;92(3): 969-975.
- Coagulation and fibrinolysis in preeclampsia and neonates. Tanjung MT et al., Clin Appl Thromb Hemost. 2005 Oct;11(4):467-473.
- Plasminogen activator inhibitors type 1 and type 2 and plasminogen activators in amniotic fluid during pregnancy. Estellés A et al., Thromb Haemost. 1990 Oct 22;64(2):281-285.
- Isolation of a new specific plasminogen activator inhibitor from pregnancy plasma. Lecander I and Astedt B, Br J Haematol. 1986 Feb;62(2):221-228.